Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.
Clinical trial NCT04139772 · UNKNOWN
Trial details
- NCT number
- NCT04139772
- Sponsor
- National Cancer Institute, Naples
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-09-01
- Primary completion
- 2023-12-01
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.